Creative Medical Technology (NASDAQ:CELZ) Posts Earnings Results, Meets Expectations

Creative Medical Technology (NASDAQ:CELZ) issued its quarterly earnings data on Friday. The company reported ($0.48) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.48), Zacks reports.

Creative Medical Technology Trading Up 1.7%

Shares of Creative Medical Technology stock opened at $3.02 on Friday. Creative Medical Technology has a 12-month low of $1.69 and a 12-month high of $6.90. The firm has a market capitalization of $7.79 million, a price-to-earnings ratio of -1.04 and a beta of 2.05. The firm’s 50 day simple moving average is $3.51 and its two-hundred day simple moving average is $2.88.

Wall Street Analysts Forecast Growth

Several analysts have commented on CELZ shares. Wall Street Zen raised shares of Creative Medical Technology to a “sell” rating in a research report on Saturday, August 9th. Zacks Research raised shares of Creative Medical Technology to a “hold” rating in a research report on Tuesday, August 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Creative Medical Technology in a research note on Wednesday. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Reduce”.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.